^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Plasma-SeqSensei™ Solid Cancer IVD Kit

    Company:
    Sysmex Corp
    Type:
    CE Marked
    Related tests:
    Details
    Evidence

    News

    2ms
    Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients with Lung Cancer (clinicaltrials.gov)
    P=N/A; N=118; Recruiting; Sponsor:Istituto Oncologico Veneto IRCCS
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    cobas® EGFR Mutation Test v2 • Plasma-SeqSensei™ Solid Cancer IVD Kit
    over1year
    Paired comparison of routine molecular screening of patient samples with advanced non-small cell lung cancer in circulating cell-free DNA using OncoBEAMTM EGFR V2, targeted next‐generation sequencing Plasma-SeqSensei™ Solid Cancer IVD Kit and custom-validated NGS assay (AACR 2023)
    Plasma-SeqSensei™ Solid Cancer IVD Kit resulted in de novo detection of targetable oncogenic drivers and resistance mechanisms in patients with NSCLC, including when tissue biopsies were inadequate for genotyping with high sensitivity and accuracy for low and high cfDNA inputs.
    Clinical • Next-generation sequencing • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    OncoBEAM EGFR v2 Kit • Plasma-SeqSensei™ Solid Cancer IVD Kit
    over1year
    Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three Targeted Assays. (PubMed, Cancers (Basel))
    "The Plasma-SeqSensei™ SOLID CANCER IVD kit resulted in de novo detection of targetable oncogenic drivers and resistance alterations, with a high sensitivity and accuracy for low and high cfDNA inputs. Thus, this assay is a sensitive, robust, and accurate test."
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR exon 20 mutation • KRAS exon 2 mutation • BRAF exon 11 mutation • BRAF exon 15 mutation
    |
    OncoBEAM EGFR v2 Kit • Plasma-SeqSensei™ Solid Cancer IVD Kit